NICE backing for Takeda’s Adcetris for rare lymphoma
Standard of care in untreated systemic anaplastic large cell lymphoma (sALCL) has not changed in several decades
Read More
Tag: brentuximab vedotin
NICE backing for Keytruda in classical Hodgkin lymphoma
The National Institute for Health and Care Excellence has recommended that MSD’s Keytruda be funded on the NHS via the Cancer Drugs Fund (CDF) for a subgroup of people with relapsed or refractory classical Hodgkin lymphoma.
Read More
US expands scope of Seattle Genetics’ Adcetris
US regulators have approved Seattle Genetics’ Adcetris in combination with chemotherapy for adult patients with previously untreated Stage III or IV classical Hodgkin lymphoma.
Read More
NICE minded to reject Keytruda for classical Hodgkin lymphoma
Cost regulators for NHS therapies in England and Wales say they are minded not to recommend funding for MSD’s Keytruda as a treatment for classical Hodgkin lymphoma, because its cost-effectiveness is uncertain.
Read More
NHS future ‘uncertain’ for Adcetris in ALCL
Cost regulators for NHS treatments in England and Wales say they are currently minded not to recommend Takeda’s Adcetris on the NHS for relapsed or refractory systemic anaplastic large cell lymphoma (ALCL), a cancer of the lymphatic system.
Read More
NICE bars Adcetris from routine NHS use for Hodgkin’s lymphoma
It is looking likely that patients with Hodgkin’s lymphoma will not be getting access to Takeda’s Adcetris on the National Health Service in England, after the drug was turned down again by cost regulators despite new data and a drop in price.
Read More
Europe expands use of Takeda’s Adcetris
Takeda has received European Commission approval for the expanded use of Adcetris as a consolidation treatment in post-transplant Hodgkin lymphoma.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
